In vivo, the DC vaccine pulsed with peptide 619 significantly suppressed tumor growth (tumor weight inhibition rate: 51.4%), increased the percentage of CD8+ T cells in peripheral blood, and enhanced the infiltration of hCD45+ cells into tumor tissues. Here, CD8A is linked to neoplasm.